Bristol-myers Squibb Compnay

Smithkline Beecham Corporation

Viiv Healthcare UK Limited

Margaret E Sorenson

B Narasimhulu Naidu

Michael A Walker

Yasutsugu Ueda

John D Matiskella

Timothy P Connolly

Manoj Patel

Jacques Banville

Francis Beaulieu

Roger Remillard

Serge Plamondon

Carl Ouellet

Jerry Leroy Adams

Kevin M Peese

Ravi Shanker Garigipati

Mark R Krystal

Barry L Johnson

Chen Li

Nicholas A Meanwell

John F Kadow

Jeffrey Charles Boehm

Alicia Regueiro-Ren

Annapurna Pendri

Joanne J Bronson

Thomas W Hudyma

Jason T Goodrich

Xiaofan Zheng

Martin D Eastgate

Oak K Kim

Michael S Bowsher

Yunhui Zhang

Zhizhen Barbara Zheng

Bin Zheng

James David Winkler

Ke Chen

Hatice Belgin Gulgeze

Dane M Springer

Francisco Gonzalez-Bobes

Rongti Li

Dawn DiGiugno

Narasimhulu B Naidu

Zhuping Ma

Yasutsuga Ueda

Jonathan R Weiss

The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for making and using these compounds in the treatment of HIV infection. 

Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication

The disclosure generally relates to the novel compounds of formula I, including their salts, which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV. 

HIV integrase inhibitors

The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection. 

Inhibitors of human immunodeficiency virus replication

The invention encompasses a series bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV. 

The invention encompasses series bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV. 

The invention encompasses a series pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV. 

The invention encompasses a series of bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.

N-[[4-fluoro-2-(5-methy-1H-1,2,4-triazol-1-yl)phenyl]methyl]-4-,6,7,9-tetrahydro-3-hydroxy-9,9-dimethyl-4-oxo-pyrimido[2,1-c][1,4]oxazine-2-carboxamide as an HIV integrase inhibitor

The invention encompasses a series of bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV. 

N-[4-Fluorophenyl)methyl]-4,6,7,9-tetrahydro-3-hydroxy-9,9-dimethyl-4-oxo-pyrimido[2,1-c][1,4]oxazine-2-carboxamide as an HIV integrase inhibitor

The invention encompasses a series cyclic bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV. 

Bicyclic heterocycles as HIV integrase inhibitors

The invention encompasses a series bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV 

Compounds useful for treating HIV are disclosed having the general formula wherein R, R, and B are as defined in the specification. Compositions containing the compounds and methods for using the compounds to inhibit HIV are also disclosed.

Compounds of the present disclosure are spirocycle-substituted pyrimidinecarboxamides. Also disclosed are pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating HIV infection and AIDS.

The present invention describes novel compounds of Formula I which inhibit HIV integrase. The invention also describes compositions and treatments of AIDS or ARC by using these compounds 

The present invention relates to a series of pyrimidine compounds of Formula I which inhibit HIV integrase and to pharmaceutical compositions and methods of treatment for AIDS or ARC using these compounds

Growing community of inventors

Meriden, CT, United States of America

Margaret E Sorenson